Pharmacokinetics of marbofloxacin after single intravenous and repeat oral administration to cats

Albarellos, G. A.; Montoya, L.; Landoni, M. F.

doi:10.1016/j.tvjl.2004.05.011

Cited by 24 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At 16°C, the bioavailability of enrofl oxacin was 66.13% in this study, which was higher than the 50.82% at 10°C and the profi les studied previously. The reported 50.82% or 66.13% bioavailability of enrofl oxacin was much lower than that of quinolones in domestic animals (Hu and Feng, 1999;Zeng et al, 2003;Albarellos et al, 2005;Dimitrova et al, 2006). However, other quinolones in turbot were reported with lower bioavailabilities than the bioavailability of enrofl oxacin, such as a 27.90% bioavailability of oxolinic acid after 10 mg/kg at 16°C, and a 59% bioavailability of fl umequine after oral administration at 10 mg/kg at 18°C (Poher, 1998;Hansen and Horsberg, 1999).…”

Section: The Comparative Pharmacokinetics Of Enrofl Oxacinmentioning

confidence: 99%

Pharmacokinetics and tissue behavior of enrofloxacin and its metabolite ciprofloxacin in turbot Scophthalmus maximus at two water temperatures

Liang

Zhao

et al. 2012

Chin. J. Ocean. Limnol.

View full text Add to dashboard Cite

Turbot Scophthalmus maximus , an important aquaculture species in China, currently suffers from epizootic diseases because of high density aquaculture. Enrofl oxacin has been used to treat various systemic bacterial fi sh infections. However, studies concerning the pharmacokinetics of enrofl oxacin in turbot are limited. In this study, the pharmacokinetics of enrofl oxacin and its metabolite ciprofl oxacin, were investigated in the turbot following intravenous and oral administration at 10 mg enrofl oxacin/kg body weight, at 16°C and 10°C water temperatures. The concentrations of enrofl oxacin and ciprofl oxacin in the main tissues (plasma, muscle, liver and kidney) were detected by HPLC. The results show that the plasma concentration-time data for enrofl oxacin were best described as a two-compartment open model after intravenous and oral administration. Three pharmacokinetic equations were established between the concentrations and temperatures. The kinetic profi le of enrofl oxacin was temperature dependent. The absorption half-life of enrofl oxacin was 1.99 h and 2.17 h after oral administration, whereas the elimination half-life of the drug was 98.63 h and 136.59 h at 16°C and 10°C, respectively. The peak concentration of enrofl oxacin in plasma and tissues was higher at 16°C than that at 10°C, and the peak plasma concentration time in the liver was the shortest at both temperatures among those of other tissues. The plasma C max /MIC ratio varied between 11.08 and 5 540.00 at 16°C; and between 7.92 and 3 960.00 at 10°C. The AUC/MIC ratio was 467.82-280 690.00 at 16°C, and 359.48-215 690.00 at 10°C. These ratios indicate that it is possible to obtain therapeutic effi cacy. Very low levels of ciprofl oxacin were detected. The AUC ratios of ciprofl oxacin and enrofl oxacin in plasma suggest that plasma ciprofl oxacin might play a minor role in enrofl oxacin treatment for turbot.

show abstract

Section: The Comparative Pharmacokinetics Of Enrofl Oxacinmentioning

confidence: 99%

Pharmacokinetics and tissue behavior of enrofloxacin and its metabolite ciprofloxacin in turbot Scophthalmus maximus at two water temperatures

Liang

Zhao

et al. 2012

Chin. J. Ocean. Limnol.

View full text Add to dashboard Cite

show abstract

“…A 13% increase in AUC and AI = 1.13 ± 0.012 suggested lack of MBF accumulation after repeated IM administration up to 5 days. Similarly, MBF accumulation was not observed in cats after repeated oral administration for 6 days (Albarellos et al, ). However, after repeated IM administration, a slight accumulation of MBF had been observed in cattle (Schneider et al, ).…”

Section: Discussionmentioning

confidence: 91%

“…There is an urgent need to set up PK/PD‐based rational dosage schedule of MBF to preserve its efficacy for treatment of infectious diseases. Pharmacokinetics of MBF were previously studied in cattle, horse, sheep, goats, poultry, turkey, dogs and cats following single dose administration (Albarellos, Montoya, & Landoni, ; Aliabadi & Lees, ; Anadon et al, ; Bousquet‐Melou, Bernard, Schneider, & Toutain, ; Regnier, Concordet, Schneider, Boisrame, & Toutain, ; Schneider et al, ; Sidhu et al, , , ; Waxman et al, ) but there is no PK/PD data following repeated MBF administration in goats. Hence, the data generated in this study provide a rational basis for determination of an optimal therapeutic dosage regimen of MBF following repeated administration to treat infectious diseases produced by E. coli and P. multocida in goats.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic–pharmacodynamic relationship of marbofloxacin for Escherichia coli and Pasturella multocida following repeated intramuscular administration in goats

Bhardwaj

Sidhu

Saini

et al. 2019

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The pharmacokinetics (PK) and pharmacodynamics (PD) of marbofloxacin (MBF) were determined in six healthy female goats of age 1.00–1.25 years after repeated administration of MBF. The MBF was administered intramuscularly (IM) at 2 mg kg−1 day−1 for 5 days. Plasma concentrations of MBF were determined by high‐performance liquid chromatography, and PK parameters were obtained using noncompartmental analysis. The MBF concentrations peaked at 1 hr, and peak concentration (Cmax) was 1.760 µg/ml on day 1 and 1.817 µg/ml on day 5. Repeated dosing of MBF caused no significant change in PK parameters except area under curve (AUC) between day 1 (AUC0–∞D1 = 7.67 ± 0.719 µg × hr/ml) and day 5 (AUC0‐∞D5 = 8.70 ± 0.857 µg × hr/ml). A slight difference in mean residence time between 1st and 5th day of administration and accumulation index (AI = 1.13 ± 0.017) suggested lack of drug accumulation following repeated IM administration up to 5 days. Minimum inhibitory concentration (MIC) demonstrated that Escherichia coli (MIC = 0.04 µg/ml) and Pasturella multocida (MIC = 0.05 µg/ml) were highly sensitive to MBF. Time‐kill kinetics demonstrated rapid and concentration‐dependent activity of MBF against these pathogens. PK/PD integration of data for E. coli and P. multocida, using efficacy indices: Cmax/MIC and AUC0–24hr/MIC, suggested that IM administration of MBF at a dose of 2 mg kg−1 day−1 is appropriate to treat infections caused by E. coli. However, a dose of 5 mg kg−1 day−1 is recommended to treat pneumonia caused by P. multocida in goats. The study indicated that MBF can be used repeatedly at dosage of 2 mg/kg in goats without risk of drug accumulation up to 5 days.

show abstract

“…Following oral administration of marbofloxacin, the mean peak serum concentrations (C max ) were 1.15±0.01 g/mL accomplished at time (T max ) 2.53±0.04 h. Marbofloxacin could be distinguished in a therapeutic concentration for 24 h after oral administration. The pharmacokinetics parameters of marbofloxacin following a single intravenous and oral administration were recorded in table (1). Oral administration of 2 mg/kg.b.wt every 24 hours for five doses in normal and E.coli infected chicken uncovered a lower significant serum marbofloxacin concentration at all-time sampling in E.coli infected chicken than in normal ones.…”

Section: Resultsmentioning

confidence: 99%

Bioavailability pharmacokinetics and residues of marbofloxacin in normal and E.coli infected broiler chicken

Elkomy¹,

Attia²,

Latif³

et al. 2016

IJPT

View full text Add to dashboard Cite

The pharmacokinetics of marbofloxacin was studied following a single intravenous, oral administration in normal broiler chickens and repeated oral administrations in normal and experimentally E.coli infected broiler chickens. The pharmacokinetic parameters following a single intravenous injection of 2 mg/kg b.wt., revealed that marbofloxacin obeyed a two compartments open model, distribution half-life (t 0.5(α) ) was 0.25±0.02 h, volume of distribution (V dss ) was 0.76±0.08 L/kg, elimination half-life (t 0 . 5(β) ) was 5.43±0.87 h and total body clearance (CL tot ) was 0.09±0.002 l/kg/h. Following a single oral administration, marbofloxacin was rapidly and efficiently absorbed through gastrointestinal tract of chickens as the absorption half-life (t 0.5 (ab) : 0.62±0.02 h). Maximum serum concentration (C max ) was 1.15±0.01 μg/ml, reached its maximum time (t max ) at 2.53±0.04 h, elimination half-life (t 0.5 (el) ) was 7.36±0.20 h indicating the tendency of chickens to eliminate marbofloxacin in slow rate. Oral bioavailability was 73.57± 1.90 % indicating good absorption of marbofloxacin after oral administration. Serum concentrations of marbofloxacin following repeated oral administration of 2 mg/kg b.wt. once daily for five consecutive days, peaked 2 hours after each oral dose with lower significant values recorded in experimentally infected broiler chickens than in normal ones. Tissues residues of marbofloxacin in slaughtered normal chickens was highly in those tissues lung, liver, and kidneys in chickens and the chicken must not be slaughtered before 3 days of stopping of drug administration. It was concluded that the in-vitro protein binding was 12.33±0.82%.

show abstract

Pharmacokinetics of marbofloxacin after single intravenous and repeat oral administration to cats

Cited by 24 publications

References 33 publications

Pharmacokinetics and tissue behavior of enrofloxacin and its metabolite ciprofloxacin in turbot Scophthalmus maximus at two water temperatures

Pharmacokinetics and tissue behavior of enrofloxacin and its metabolite ciprofloxacin in turbot Scophthalmus maximus at two water temperatures

Pharmacokinetic–pharmacodynamic relationship of marbofloxacin for Escherichia coli and Pasturella multocida following repeated intramuscular administration in goats

Bioavailability pharmacokinetics and residues of marbofloxacin in normal and E.coli infected broiler chicken

Contact Info

Product

Resources

About